Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label afatinib trial in HER2-negative metastatic breast cancer
2006-002018-36Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of afatinib in breast cancer (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Objective response in Cohort B and Clinical benefit in Cohort A. Started Jul 2006; status: terminated.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-002018-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002018-36.